


Genesis MedTech introduces China's first domestic brand of NPMA-approved antibacterial sutures

12 September 2023 | News

Newly developed antibacterial sutures are coated with triclosan, a broad-spectrum antimicrobial agent



Singapore-based Genesis MedTech, a leading medical device company, has announced that its absorbable sutures with antibacterial protection have successfully obtained approval from the China's National Medical Products Administration (NMPA) for market release.

The newly developed antibacterial sutures are coated with triclosan, a broad-spectrum antimicrobial agent with activity against gram-positive and gram-negative bacteria. These advanced sutures effectively inhibit the growth of *Staphylococcus aureus*, *Staphylococcus epidermidis*, methicillin-resistant *Staphylococcus aureus* (MRSA), methicillin-Resistant *Staphylococcus epidermidis* (MRSE), thereby significantly reducing the risk of surgical site infections.

Surgical site infections are one of the most frequently reported types of hospital-acquired infection and are associated with substantial clinical and economic burdens. Authoritative institutions, including the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), have issued guidelines for the prevention of surgical site infection and unequivocally affirmed the effectiveness of antimicrobial agent-coated sutures in lowering the risk of surgical site infections across diverse surgical procedures.

Alongside the highly anticipated absorbable antibacterial sutures, Genesis MedTech continues to expand its suture product lines with comprehensive offerings. The company achieved a significant milestone in September 2022 with the NMPA approval of its barbed sutures. Furthermore, its barbed absorbable sutures with black needle, non-absorbable surgical polypropylene sutures, and controlled-release needle sutures have been widely used in thousands of hospitals nationwide.